Cancer therapeutics: Targeting the dark side of Myc

被引：126

作者：

Ponzielli, R ^{[1
]}

Katz, S ^{[1
]}

Barsyte-Lovejoy, D ^{[1
]}

Penn, LZ ^{[1
]}

机构：

[1] Univ Toronto, Princess Margaret Hosp, Div Canc Genom & Proteom, Ontario Canc Inst,Dept Med Biophys, Toronto, ON M5G 2M9, Canada

来源：

EUROPEAN JOURNAL OF CANCER | 2005年 / 41卷 / 16期

基金：

加拿大健康研究院;

关键词：

Myc; Max; therapeutics; deregulation; transformation; target genes; protein-protein interactors; siRNA; antisense oligonucleotides; ChIP-chip; cancer;

D O I：

10.1016/j.ejca.2005.08.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The potent Myc oncoprotein plays a pivotal role as a regulator of tumorigenesis in numerous human cancers of diverse origin. Experimental evidence shows that inhibiting Myc significantly halts tumour cell growth and proliferation. This review summarises recent progress in understanding the function of Myc as a transcription factor, with emphasis on key protein interactions and target gene regulation. In addition, major advances in drug development aimed at eliminating Myc are described, including antisense and triple helix forming oligonucleotides, porphyrins and siRNA. Future anti-Myc strategies are also discussed that inhibit Myc at the level of expression and/or function. Targeting the dark side of Myc with novel therapeutic agents promises to have a profound impact in combating cancer. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：2485 / 2501

页数：17

共 198 条

[1] c-Myc is necessary for DNA damage-induced apoptosis in the G2 phase of the cell cycle [J].

Adachi, S ;

Obaya, AJ ;

Han, ZY ;

Ramos-Desimone, N ;

Wyche, JH ;

Sedivy, JM .

MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (15) :4929-4937

[2]

Amati B., 2001, BIOCHIM BIOPHYS ACTA, V1471, P135

[3] c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription [J].

Arabi, A ;

Wu, SQ ;

Ridderstråle, K ;

Bierhoff, H ;

Shiue, C ;

Fatyol, K ;

Fahlén, S ;

Hydbring, P ;

Söderberg, O ;

Grummt, I ;

Larsson, LG ;

Wright, APH .

NATURE CELL BIOLOGY, 2005, 7 (03) :303-310

[4] c-Myc activation in transgenic mouse epidermis results in mobilization of stem cells and differentiation of their progeny [J].

Arnold, I ;

Watt, FM .

CURRENT BIOLOGY, 2001, 11 (08) :558-568

[5] YY1 can inhibit c-Myc function through a mechanism requiring DNA binding of YY1 but neither its transactivation domain nor direct interaction with c-Myc [J].

Austen, M ;

Cerni, C ;

Lüscher-Firzlaff, JM ;

Lüscher, B .

ONCOGENE, 1998, 17 (04) :511-520

[6] c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism [J].

Barsyte-Lovejoy, D ;

Mao, DYL ;

Penn, LZ .

ONCOGENE, 2004, 23 (19) :3481-3486

[7] Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts [J].

Berg, T ;

Cohen, SB ;

Desharnais, J ;

Sonderegger, C ;

Maslyar, DJ ;

Goldberg, J ;

Boger, DL ;

Vogt, PK .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (06) :3830-3835

[8] Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo [J].

Bertrand, JR ;

Pottier, M ;

Vekris, A ;

Opolon, P ;

Maksimenko, A ;

Malvy, C .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 296 (04) :1000-1004

[9] POINT MUTATIONS IN THE C-MYC TRANSACTIVATION DOMAIN ARE COMMON IN BURKITTS-LYMPHOMA AND MOUSE PLASMACYTOMAS [J].

BHATIA, K ;

HUPPI, K ;

SPANGLER, G ;

SIWARSKI, D ;

IYER, R ;

MAGRATH, I .

NATURE GENETICS, 1993, 5 (01) :56-61

[10] C-myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells [J].

Biroccio, A ;

Benassi, B ;

Amodei, S ;

Gabellini, C ;

Del Bufalo, D ;

Zupi, G .

MOLECULAR PHARMACOLOGY, 2001, 60 (01) :174-182

← 1 2 3 4 5 6 7 8 9 10 →